Serum amyloid A concentrations, COVID-19 severity and mortality : An updated systematic review and meta-analysis
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved..
BACKGROUND AND OBJECTIVES: An excessive inflammatory response in patients with coronavirus disease 2019 (COVID-19) is associated with high disease severity and mortality. Specific acute phase reactants might be useful for risk stratification. A systematic review and meta-analysis was conducted of studies on serum amyloid A (SAA) in patients with COVID-19.
METHODS: The PubMed, Web of Science, and Scopus databases were searched, covering the period January 2020 to December 2020, for studies reporting SAA concentrations, COVID-19 severity, and survival status.
RESULTS: Nineteen studies involving 5617 COVID-19 patients were included in the meta-analysis. Pooled results showed that SAA concentrations were significantly higher in patients with severe disease and non-survivors (standard mean difference (SMD) 1.20, 95% confidence interval 0.91-1.49, P < 0.001). Extreme between-study heterogeneity was observed (I2 = 92.4%, P < 0.001). In the sensitivity analysis, the effect size was not significantly affected when each study was removed in turn (range 1.10-1.29). The Begg test (P = 0.030), but not the Egger test (P = 0.385), revealed the presence of publication bias. Pooled SMD values were significantly and positively associated with sex (t = 2.20, P = 0.047) and aspartate aminotransferase (t = 3.44, P = 0.014).
CONCLUSIONS: SAA concentrations were significantly and positively associated with higher COVID-19 severity and mortality. This acute phase reactant might assist with risk stratification and monitoring in this group.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:105 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 105(2021) vom: 30. Apr., Seite 668-674 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zinellu, Angelo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aspartate Aminotransferases |
|---|
| Anmerkungen: |
Date Completed 24.05.2021 Date Revised 24.05.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2021.03.025 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322936349 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322936349 | ||
| 003 | DE-627 | ||
| 005 | 20231225183109.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2021.03.025 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1076.xml |
| 035 | |a (DE-627)NLM322936349 | ||
| 035 | |a (NLM)33737133 | ||
| 035 | |a (PII)S1201-9712(21)00243-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zinellu, Angelo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serum amyloid A concentrations, COVID-19 severity and mortality |b An updated systematic review and meta-analysis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.05.2021 | ||
| 500 | |a Date Revised 24.05.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND AND OBJECTIVES: An excessive inflammatory response in patients with coronavirus disease 2019 (COVID-19) is associated with high disease severity and mortality. Specific acute phase reactants might be useful for risk stratification. A systematic review and meta-analysis was conducted of studies on serum amyloid A (SAA) in patients with COVID-19 | ||
| 520 | |a METHODS: The PubMed, Web of Science, and Scopus databases were searched, covering the period January 2020 to December 2020, for studies reporting SAA concentrations, COVID-19 severity, and survival status | ||
| 520 | |a RESULTS: Nineteen studies involving 5617 COVID-19 patients were included in the meta-analysis. Pooled results showed that SAA concentrations were significantly higher in patients with severe disease and non-survivors (standard mean difference (SMD) 1.20, 95% confidence interval 0.91-1.49, P < 0.001). Extreme between-study heterogeneity was observed (I2 = 92.4%, P < 0.001). In the sensitivity analysis, the effect size was not significantly affected when each study was removed in turn (range 1.10-1.29). The Begg test (P = 0.030), but not the Egger test (P = 0.385), revealed the presence of publication bias. Pooled SMD values were significantly and positively associated with sex (t = 2.20, P = 0.047) and aspartate aminotransferase (t = 3.44, P = 0.014) | ||
| 520 | |a CONCLUSIONS: SAA concentrations were significantly and positively associated with higher COVID-19 severity and mortality. This acute phase reactant might assist with risk stratification and monitoring in this group | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Disease severity | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Serum amyloid A | |
| 650 | 7 | |a Serum Amyloid A Protein |2 NLM | |
| 650 | 7 | |a Aspartate Aminotransferases |2 NLM | |
| 650 | 7 | |a EC 2.6.1.1 |2 NLM | |
| 700 | 1 | |a Paliogiannis, Panagiotis |e verfasserin |4 aut | |
| 700 | 1 | |a Carru, Ciriaco |e verfasserin |4 aut | |
| 700 | 1 | |a Mangoni, Arduino A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 105(2021) vom: 30. Apr., Seite 668-674 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:105 |g year:2021 |g day:30 |g month:04 |g pages:668-674 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2021.03.025 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 105 |j 2021 |b 30 |c 04 |h 668-674 | ||